Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.
Agoracom
The Small Cap Epicenter
The Small Cap Epicenter
AGORACOM WIRE - FRIDAY MAY 25TH, 2012
FOCUS METALS (TSXV:FMS) Changes Its Name to Focus Graphite Inc.
Read More | *SPONSOR
INTERNATIONAL PBX VENTURES (TSX:PBX) Signs Copaquire Joint Venture Option Agreement - $90M Potential Payment Read More
AGORACOM Maintenance Alert: Friday Evening Downtime for About an Hour Read More
LOMIKO METALS (TSXV:LMR) Graphite and Zinc Price Outlook is Favourable Through 2013 Read More | *SPONSOR
Isotechnika Inc. granted patent for mTOR inhibitor |  | |
 |
Isotechnika Inc. announced today that the process of nationalizing European Patent No. 1644392 has commenced with the issuance of a Swedish Patent for its mTOR inhibitor, TAFA93. In accordance with the European Patent Convention, this patent will be granted in a total of 31 European countries of which patents for the remaining 30 countries will be forthcoming. "Our medical device partnership with Atrium Medical makes use of TAFA93 on Atrium's drug eluting stent technology," stated Dr. Robert Foster, Isotechnika's Chairman & CEO. "This allows us to broaden our product pipeline while maintaining our primary focus in transplantation." About TAFA93 ------------ The Company's second drug in development is TAFA93, an advanced pro-drug of rapamycin. TAFA93 is a novel small molecule mTOR inhibitor, which is a class of drugs currently used in the prevention of organ rejection in transplantation. mTOR inhibitors are typically used in combination with calcineurin inhibitors after organ transplant. These anti-proliferative mTOR inhibitors also have utility in oncology and as drug coating for coronary stents and surgical meshes. The drug-eluting stent market was estimated at $5.5B in 2005. TAFA93 has successfully completed Phase 1 clinical trials. About Isotechnika ----------------- Edmonton-based Isotechnika Inc. is an international biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics that are designed to offer advantages over other currently available treatments. There is a significant unmet medical need in the treatment of both solid organ transplantation and autoimmune disease. It is estimated that the market potential exceeds $2 billion annually in sales for calcineurin inhibitors such as ISA247. ISA247 is currently being investigated in a Phase 2b North American trial for the prevention of kidney graft rejection subsequent to transplantation and a Phase 3 European/Canadian psoriasis trial. Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol "ISA". More information on Isotechnika can be found at www.isotechnika.com. Partnerships with Isotechnika Inc. ---------------------------------- << - Roche retains an option to continue development of the transplant indications based on the successful completion of the ongoing Phase 2b kidney transplant trial. - Atrium Medical Corporation has exclusive worldwide licensing agreement for use of ISA247 and TAFA93 with drug eluting devices for non-systemic treatment of vascular, cardiovascular, target vessel and issue disorders. - Lux Biosciences Inc. was granted worldwide rights to develop and commercialize ISA247 for the treatment and prophylaxis of all ophthalmic diseases. |
Please login to post a reply
Like Isotechnika? Then you might also be interested in Star Navigation Systems Group Ltd.
